Logo image of 88Q.DE

4BASEBIO PLC (88Q.DE) Stock Fundamental Analysis

Europe - FRA:88Q - GB00BMCLYF79 - Common Stock

9.85 EUR
+0.35 (+3.68%)
Last: 9/10/2025, 7:00:00 PM
Fundamental Rating

4

Taking everything into account, 88Q scores 4 out of 10 in our fundamental rating. 88Q was compared to 73 industry peers in the Biotechnology industry. The financial health of 88Q is average, but there are quite some concerns on its profitability. 88Q shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

88Q had negative earnings in the past year.
In the past year 88Q has reported a negative cash flow from operations.
In the past 5 years 88Q always reported negative net income.
88Q had a negative operating cash flow in each of the past 5 years.
88Q.DE Yearly Net Income VS EBIT VS OCF VS FCF88Q.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -27.57%, 88Q is in line with its industry, outperforming 51.43% of the companies in the same industry.
88Q has a Return On Equity (-46.75%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -27.57%
ROE -46.75%
ROIC N/A
ROA(3y)-45.31%
ROA(5y)-32.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
88Q.DE Yearly ROA, ROE, ROIC88Q.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

88Q's Gross Margin of 67.52% is fine compared to the rest of the industry. 88Q outperforms 61.43% of its industry peers.
In the last couple of years the Gross Margin of 88Q has declined.
The Profit Margin and Operating Margin are not available for 88Q so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.33%
GM growth 5YN/A
88Q.DE Yearly Profit, Operating, Gross Margins88Q.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

6

2. Health

2.1 Basic Checks

88Q does not have a ROIC to compare to the WACC, probably because it is not profitable.
88Q has more shares outstanding than it did 1 year ago.
The number of shares outstanding for 88Q has been increased compared to 5 years ago.
Compared to 1 year ago, 88Q has an improved debt to assets ratio.
88Q.DE Yearly Shares Outstanding88Q.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
88Q.DE Yearly Total Debt VS Total Assets88Q.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

88Q has an Altman-Z score of 3.61. This indicates that 88Q is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 88Q (3.61) is better than 81.43% of its industry peers.
A Debt/Equity ratio of 0.57 indicates that 88Q is somewhat dependend on debt financing.
88Q has a Debt to Equity ratio (0.57) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF N/A
Altman-Z 3.61
ROIC/WACCN/A
WACC8.55%
88Q.DE Yearly LT Debt VS Equity VS FCF88Q.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 11.30 indicates that 88Q has no problem at all paying its short term obligations.
88Q's Current ratio of 11.30 is amongst the best of the industry. 88Q outperforms 94.29% of its industry peers.
88Q has a Quick Ratio of 11.18. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.
88Q has a better Quick ratio (11.18) than 94.29% of its industry peers.
Industry RankSector Rank
Current Ratio 11.3
Quick Ratio 11.18
88Q.DE Yearly Current Assets VS Current Liabilites88Q.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for 88Q have decreased strongly by -51.13% in the last year.
The Revenue has grown by 84.39% in the past year. This is a very strong growth!
Measured over the past years, 88Q shows a very strong growth in Revenue. The Revenue has been growing by 35.80% on average per year.
EPS 1Y (TTM)-51.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.4%
Revenue 1Y (TTM)84.39%
Revenue growth 3Y40.28%
Revenue growth 5Y35.8%
Sales Q2Q%125.75%

3.2 Future

88Q is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.80% yearly.
88Q is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 96.33% yearly.
EPS Next Y-7.86%
EPS Next 2Y-34.73%
EPS Next 3Y-15.5%
EPS Next 5Y14.8%
Revenue Next Year129.21%
Revenue Next 2Y173.86%
Revenue Next 3Y137.13%
Revenue Next 5Y96.33%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
88Q.DE Yearly Revenue VS Estimates88Q.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
88Q.DE Yearly EPS VS Estimates88Q.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 88Q. In the last year negative earnings were reported.
Also next year 88Q is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
88Q.DE Price Earnings VS Forward Price Earnings88Q.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
88Q.DE Per share data88Q.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as 88Q's earnings are expected to decrease with -15.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.73%
EPS Next 3Y-15.5%

More info and screens

0

5. Dividend

5.1 Amount

88Q does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4BASEBIO PLC

FRA:88Q (9/10/2025, 7:00:00 PM)

9.85

+0.35 (+3.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-23 2024-09-23
Earnings (Next)N/A N/A
Inst Owners13.58%
Inst Owner ChangeN/A
Ins Owners10.96%
Ins Owner ChangeN/A
Market Cap153.07M
Analysts84.44
Price Target19.3 (95.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.67%
PT rev (3m)-6.41%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)44.58%
EPS NY rev (3m)44.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 141.86
P/FCF N/A
P/OCF N/A
P/B 5.02
P/tB 5.78
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.92
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.07
BVpS1.96
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.57%
ROE -46.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.52%
FCFM N/A
ROA(3y)-45.31%
ROA(5y)-32.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.33%
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 168.38%
Cap/Sales 168.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.3
Quick Ratio 11.18
Altman-Z 3.61
F-Score5
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)276.3%
Cap/Depr(5y)321.58%
Cap/Sales(3y)395.7%
Cap/Sales(5y)363.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.4%
EPS Next Y-7.86%
EPS Next 2Y-34.73%
EPS Next 3Y-15.5%
EPS Next 5Y14.8%
Revenue 1Y (TTM)84.39%
Revenue growth 3Y40.28%
Revenue growth 5Y35.8%
Sales Q2Q%125.75%
Revenue Next Year129.21%
Revenue Next 2Y173.86%
Revenue Next 3Y137.13%
Revenue Next 5Y96.33%
EBIT growth 1Y-49.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.65%
EBIT Next 3Y9.16%
EBIT Next 5Y15.27%
FCF growth 1Y-60.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.91%
OCF growth 3YN/A
OCF growth 5YN/A